Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Find studies

Showing 801–825 of 833 studies in Caregiving (page 33 of 34) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

What “Caregiving” covers

Caregiving — Research on the people doing the caring: their health, their workload, and what support actually helps.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Emerging themes include (1) receptive to ACP, (2) mixed emotions, (3) barriers to ACP, (4) family consensus in decision-making, and (5) benefits of ACP. 5 key findings →

Evidence: low

• AT use was limited and AT type used varied by caregiver living arrangement. • Most used ATs: daily living support and risk prevention; risk response least used. • Daily living support ATs linked to fewer care hours. • Risk prevention ATs tied to longer PT, higher CarerQol-7D, and lower SRB scores. • Daily support and risk response ATs most likely to extend PT by over six months. 4 key findings →

Evidence: low

Progressive functional decline and behavioral disturbances in people with dementia place sustained emotional and practical demands on family caregivers, often resulting in chronic stress, anxiety, depression, and a high perceived caregiving burden. 2 key findings →

Evidence: low

Respite for individuals caring for family living with dementia is a common way to take personal time away from caregiving. 2 key findings →

Evidence: low

Caring While Moving: Case Studies on Physical Activity and Dementia Caregiver Well-Being

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Healthcare 2025-09-03

While both caregivers participated in physical activity, their case studies reveal opportunities to optimize physical activity interventions to support members of the caregiving dyad: (1) targeting mitochondrial fitness—the ability of mitochondria to maintain energy homeostasis with aging—so participants can mitigate the onset of NCDs, fatigue, and overall health outcomes; (2) promoting the self-care and psychological benefits of physical activity such as improved mood and social connectedness; and (3) improving the accurate perceptions of participants’ health and physical activity with specific measurable markers of physical activity. 2 key findings →

Evidence: low

These observations: (i) support the hypothesis of transneuronal spread of neurofibrillary changes from the DR to its interconnected cortical brain areas; and (ii) indicate that the supratrochlear subnucleus of the DR is affected by neurofibrillary changes before the transentorhinal cortex during the disease process underlying AD. 2 key findings →

Evidence: low

This study explores how older people with dementia and their family caregivers experience the process from diagnosis to follow-up in primary care, what support is needed, what works well and what could be improved. 2 key findings →

Evidence: low

Caregiving interventions can reduce caregiver burden and promote caregiver competence, yet caregiving is rooted in culture, with differing impacts of the caregiving role. 5 key findings →

Evidence: low

The analysis revealed six main themes: 'Core health care challenges,' 'communication approaches and information sharing,' 'role of GP,' 'situation of caregivers,' 'influence on caregiver-GP relationship,' and 'socio-cultural barriers and care preferences'. 5 key findings →

Evidence: low

Caregiver Identity and Resilience Across and Beyond Dementia Care: A Qualitative Study

✓ Peer-reviewed alzhub usefulness score 29 out of 100. Innovation in Aging 2025-12-01

With increasing dementia prevalence and reliance on spousal care partners, understanding how caregiving identity evolves and how resilience is fostered across the care trajectory is crucial. 5 key findings →

Evidence: low

Further research with DEMQOL is needed to confirm these findings in an independent sample, evaluate responsiveness, investigate the feasibility of use in specific subgroups and in economic evaluation, and develop population norms. 2 key findings →

Participants: 130 Evidence: low

Future studies are encouraged to adopt personalized internet-based supportive interventions to improve the health of family caregivers and their care recipients. 3 key findings →

Design: systematic review Evidence: high

BackgroundAlzheimers Disease and Related Dementias (ADRD) is a growing global public health challenge, and caregivers experience high rates of burden, unmet needs, and system failures. 1 key finding →

Evidence: low

Prior work suggests that perceived value may shape online support use, yet practical and trust-related barriers may still impede uptake even when beliefs are favorable. 5 key findings →

Design: cross-sectional Evidence: low

GRACE has demonstrated clinical and cost-effectiveness in trial settings, providing a strong foundation for wider implementation. 2 key findings →

Participants: 19 Evidence: low

The conventional model (M2) concordance index (C-index) was 0.680, but fell to 0.649 when missingness indicators were removed. 4 key findings →

Participants: 1,643 Evidence: low

M2 C-index 0.682, M3 0.692, M4 0.687. Adding the dyadic mean yielded an estimated ΔC of 0.010 (95% CI -0.003 to 0.024). 4 key findings →

Participants: 1,762 Evidence: moderate

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed